Pharmaceutical Executive-12-01-2022

Biopharma’s Untapped Value: The Quest to Reverse First-Launch Failure Trends

December 08, 2022

Features

42

12

Emerging biopharma companies are critical to the vibrancy of the healthcare landscape, but their long road of drug development fails to translate to successful market launch more often than it does for large pharma. What can be done to improve those odds?

2023 Pipeline Report: Testing the Limits

December 08, 2022

Features

42

12

Our annual report spotlighting notable investments in new drug development captures a mix of gradual gains and giant leaps—both equally as promising—in five expanding and diverse therapeutic areas: spinal muscular atrophy, hemophilia A, intranasal and inhaled vaccines, gene-targeted therapy, and RNA therapeutics.

Business and Passion

December 08, 2022

Executive Profile

42

12

Kimberly Moran, head of rare diseases in the US for UCB, started off working in medicine but quickly learned the importance of the business side of industry—and its role in helping improve the diagnosis and access paths for underserved patient segments.